Dare Bioscience Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
DARE Nasdaq 8731 https://www.darebioscience.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Dare Bioscience Inc

Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023 - Mar 23rd, 2023 12:00 pm
Daré Bioscience to Present at the 35th Annual Roth Conference - Mar 1st, 2023 1:00 pm
Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1 - Feb 22nd, 2023 1:00 pm
Daré Bioscience to Participate in Three February Conferences - Feb 1st, 2023 1:00 pm
Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause - Jan 26th, 2023 1:00 pm
Daré Bioscience (NASDAQ:DARE) investors are sitting on a loss of 49% if they invested five years ago - Jan 21st, 2023 12:16 pm
All You Need to Know About Dare Bioscience, Inc. (DARE) Rating Upgrade to Strong Buy - Jan 9th, 2023 5:00 pm
Daré Bioscience Announces Positive Pharmacokinetic (PK) Results from the DARE-HRT1 Phase 1 / 2 Study that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause - Jan 9th, 2023 1:00 pm
Daré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea - Dec 12th, 2022 1:00 pm
We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully - Dec 11th, 2022 2:58 pm
Dare Bioscience, Inc. (DARE) Upgraded to Buy: What Does It Mean for the Stock? - Nov 15th, 2022 5:00 pm
Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health - Nov 15th, 2022 1:00 pm
Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study - Nov 14th, 2022 1:00 pm
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates - Nov 10th, 2022 12:05 pm
Daré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update - Nov 10th, 2022 10:45 am
Daré Bioscience to Present at the Stifel 2022 Healthcare Conference - Nov 8th, 2022 1:00 pm
Daré Bioscience to Host Third Quarter 2022 Financial Results and Company Update Conference Call and Webcast on November 10, 2022 - Nov 3rd, 2022 12:00 pm
Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete - Nov 1st, 2022 12:00 pm
Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study - Oct 17th, 2022 12:00 pm
Daré Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive - Oct 10th, 2022 12:00 pm